Shepherd Center, Inc. | Hulse Spinal Cord Injury Lab

Research site

(Unclaimed)

Location

2020 Peachtree Road NW, Atlanta, Georgia, United States of America

Site insights

Top conditions

Top treatments

Natalizumab

Nabiximols

Elezanumab

Ocrelizumab

Ofatumumab

IMU-838

PIPE-307

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 14 total trials

PoNS® Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Single-Arm Study

Primary Objective: To further evaluate the aspects of safety related to PoNS therapy in chronic stroke survivors.Secondary Objectives: To further eva...

Enrolling

Chronic Stroke Survivors

Device: Portable Neuromodulation Stimulator (PoNS)

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identi...

Active, not recruiting

Multiple Sclerosis, Relapsing

Drug: Ocrelizumab

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI)

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people expe...

Active, not recruiting

Spinal Cord Injury (SCI)

Drug: Placebo

Drug: Elezanumab

Scale Up of Project Workout on Wheels Internet Intervention (WOWii)

This study is designed is to test the feasibility, fidelity, and effectiveness of scaling up an evidence- and theory-based virtually delivered physic...

Active, not recruiting

Spinal Cord Injuries

Behavioral: WOWii Program

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of...

Active, not recruiting

Relapse Remitting Multiple Sclerosis

Drug: Ofatumumab

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects w...

Enrolling

Spasticity, Cerebral or Spinal Condition

Device: iovera° system

Device: sham iovera° system treatment

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic...

Enrolling

Spinal Cord Injury

Biological: Placebo

Biological: MT-3921

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressiv...

Active, not recruiting

Multiple Sclerosis

Drug: Placebo matching IMU-838

Drug: IMU-838

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis (VISTA)

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Enrolling

Relapsing Remitting Multiple Sclerosis

Drug: Placebo

Drug: PIPE-307 Dose B